Supernus Pharmaceuticals, Inc. (SUPN) Fair Value 2026 — DCF & Multi-Method Analysis | EvidInvest | EvidInvest

SUPN — Fair Value Analysis

Supernus Pharmaceuticals, Inc.

Current: $49.03Overvalued

Fair Value Range

Bear Case (25th pct.)

$-2.03

-104.1% vs price

Base Case (Median)

$6.66

-86.4% vs price

Bull Case (75th pct.)

$7.10

-85.5% vs price

$-2.03$6.66$7.10

◇ = Current price | |Bear |Base | Bull

Method Breakdown

Method	Est. Value	vs Price	Weight
DCF (Discounted Cash Flow)	$-10.72	-121.9%	High (40%)
EV/EBITDA	$7.53	-84.6%	Medium (20%)
EV/FCF	$6.66	-86.4%	Medium (20%)

Interpretation

Based on 3 out of 8 methods, SUPN appears overvalued at the current price of $49.03. The base case fair value of $6.66 implies 86.4% downside.

Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.